France · Delayed Price · Currency is EUR Medesis Pharma Statistics
Total Valuation
Medesis Pharma has a market cap or net worth of EUR 1.77 million. The enterprise value is 5.05 million.
| Market Cap | 1.77M |
| Enterprise Value | 5.05M |
Important Dates
The last earnings date was Thursday, April 17, 2025.
| Earnings Date | Apr 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Medesis Pharma has 5.06 million shares outstanding. The number of shares has increased by 16.20% in one year.
| Current Share Class | 5.06M |
| Shares Outstanding | 5.06M |
| Shares Change (YoY) | +16.20% |
| Shares Change (QoQ) | -6.29% |
| Owned by Insiders (%) | 15.02% |
| Owned by Institutions (%) | 0.59% |
| Float | 4.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.83 |
| PB Ratio | -0.35 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.61 |
| EV / Sales | 79.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.46
| Current Ratio | 0.46 |
| Quick Ratio | 0.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -115.30% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 207.11% |
| Revenue Per Employee | 6,364 |
| Profits Per Employee | -313,410 |
| Employee Count | 10 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 13.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.98% in the last 52 weeks. The beta is 0.18, so Medesis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -73.98% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.45 |
| Relative Strength Index (RSI) | 40.91 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medesis Pharma had revenue of EUR 63,640 and -3.13 million in losses. Loss per share was -0.61.
| Revenue | 63,640 |
| Gross Profit | -2.07M |
| Operating Income | -3.53M |
| Pretax Income | -3.57M |
| Net Income | -3.13M |
| EBITDA | -3.26M |
| EBIT | -3.53M |
| Loss Per Share | -0.61 |
Balance Sheet
The company has 24,750 in cash and 3.30 million in debt, giving a net cash position of -3.27 million or -0.65 per share.
| Cash & Cash Equivalents | 24,750 |
| Total Debt | 3.30M |
| Net Cash | -3.27M |
| Net Cash Per Share | -0.65 |
| Equity (Book Value) | -5.10M |
| Book Value Per Share | -0.99 |
| Working Capital | -2.07M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,549.18% |
| Pretax Margin | -5,602.42% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medesis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.20% |
| Shareholder Yield | -16.20% |
| Earnings Yield | -176.93% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medesis Pharma has an Altman Z-Score of -21.25. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.25 |
| Piotroski F-Score | n/a |